A new bill giving the UK regulator more powers after Brexit has been welcomed by the life sciences industry. However, observers have warned that it needs fleshing out with detail, and that the government would be wise to proceed carefully if it considers relaxing clinical trial regulations.

If the UK leaves the EU without a deal at the end of this month, pharmaceutical companies will be able to book space for medicine deliveries on ferries run by four operators between UK and EU ports. 

Life science firms wanting to avoid possible blockages at the Channel ports if the UK leaves the EU without a deal are being advised by the BioIndustry Association to register now. Meanwhile the government has published a report that brings together all its advice on preparing for a no-deal Brexit.

Life science firms wanting to avoid possible blockages at the Channel ports if the UK leaves the EU without a deal are being advised by the BioIndustry Association to register now. Meanwhile the government has published a report that brings together all its advice on preparing for a no-deal Brexit.

The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.

The newly launched 2019 edition of the World Health Organization’s antibiotic database will help countries to monitor and manage antibiotic use as part of the global drive to stem the tide of antimicrobial resistance.